At present our laboratory is working on two interconnected topics of  “enhancing drug efficacy” and "phage therapy" in mycobacterium towards a long term goal of eliminating development of antimicrobial resistance (AMR) in tuberculosis (TB) and shortening treatment time for TB. Research on these projects are primarily focused on identifying key determinants of phenotypic and genetic resistance.  We  employ proteomic, metabolomic and chemical genomic tools to decipher novel mechanism of resistance in Mycobacterium.

​

In another project we are trying to understand the nature, quantum and sequence of adaptive events leading to antibiotic tolerance in mycobacteria, which is an important goal for TB researchers while developing resistant proof therapeutics. 

​

​

Finding from our past (2012) work: 50-year-old antibiotic could be another answer to TB

A half-a-century old antibiotic may re-emerge as a new medicine against tuberculosis that kills millions every year in India and other parts of the world. DECCANHERALD.COM